Spanish Breast Cancer Research Group
- Country
- 🇪🇸Spain
- Ownership
- Private
- Established
- 1995-01-01
- Employees
- 101
- Market Cap
- -
- Website
- https://www.geicam.org
Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)
- Conditions
- Advanced Breast Cancer
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 32
- Registration Number
- NCT03829306
- Locations
- 🇪🇸
Hospital del Mar, Barcelona, Cataluña, Spain
🇪🇸Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
🇪🇸Hospital General Universitario Gregorio Marañón, Madrid, Spain
Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk
- Conditions
- Breast Cancer, Male
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 777
- Registration Number
- NCT03800355
- Locations
- 🇪🇸
Hospital Universitario de Móstoles, Móstoles, Madrid, Spain
🇪🇸Hospital Universitario Donostia, Donostia-San Sebastián, Guipúzcoa, Spain
🇪🇸Hospital Universitario Quirónsalud Madrid, Pozuelo De Alarcón, Madrid, Spain
Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies
- Conditions
- Invasive Breast Cancer Early Stages
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 8000
- Registration Number
- NCT03390894
- Locations
- 🇪🇸
Centro Oncológico de Galicia, A Coruña, Spain
🇪🇸Complejo Hospitalario Universitario de Albacete, Albacete, Spain
🇪🇸Hospital Infanta Cristina, Badajoz, Spain
Retrospective Observational Study About Evolution of Patients With Breast Cancer in Hospitals From GEICAM Group
- Conditions
- Invasive Breast Cancer Between 2002 and 2005
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 13135
- Registration Number
- NCT03210974
- Locations
- 🇪🇸
Hospital Universitario Canarias, La Laguna, Santa Cruz De Tenerife, Spain
🇪🇸Hospital General Universitario de Elda - Virgen de la Salud, Elda, Alicante, Spain
🇪🇸Hospital General Universitario de Elche, Elche, Alicante, Spain
Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 11
- Registration Number
- NCT03205761
- Locations
- 🇪🇸
Hospital Universitario San Joan de Reus, Reus, Tarragona, Spain
🇪🇸Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital Universitario Vall d´Hebron, Barcelona, Spain
Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 36
- Registration Number
- NCT03025880
- Locations
- 🇪🇸
Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain
🇪🇸Hospital Universitario de Canarias, La Laguna, Canarias, Spain
🇪🇸Institut Català d'Oncologia. Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
- Conditions
- Breast Neoplasms
- Interventions
- Other: No intervention
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 1867
- Registration Number
- NCT02819882
- Locations
- 🇪🇸
Hospital General de Elche, Elche, Alicante, Spain
🇪🇸Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain
🇪🇸Hospital Universitario Donostia, San Sebastián, Donostia, Spain
Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 189
- Registration Number
- NCT02690480
- Locations
- 🇮🇪
Bon Secours Hospital, Cork, Ireland
🇮🇪Galway University Hospital, Galway, Ireland
🇮🇪Beaumont Hospital, Dublin, Ireland
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 693
- Registration Number
- NCT02028507
- Locations
- 🇮🇱
Sheba Medical Center, Tel Hashomer, Israel
🇦🇹Universitätsklinik für Innere Medizin III, Salzburg, Austria
🇦🇹Landes-Krankenhaus Steyr, Steyr, Austria
Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients
- First Posted Date
- 2014-01-06
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 12
- Registration Number
- NCT02027376
- Locations
- 🇪🇸
Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
🇪🇸Hospital General Universitario Gregorio Marañón, Madrid, Spain
🇪🇸Hospital Clínico Universitario San Carlos, Madrid, Spain